| What's New |
Biomoda Hires Manzano Strategies, Inc. to Spearhead Government
Affairs Efforts
ALBUQUERQUE, N.M., Oct. 25 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin
Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, maker of early lung cancer
detection testing and other cancer diagnostic technology, announced today it hired
Manzano Strategies LLC, a government consulting firm focused on building government
partnerships with companies interested in defense appropriations and development of
advanced technologies.
Manzano Strategies’ (http://www.manzanostrategies.com) partners David Montoya and
Bruce Donisthorpe will spearhead efforts with the New Mexico legislature and federal
government in promoting programs using Biomoda’s early lung cancer detection
technology based on a patented porphyrin application that preferentially binds to
cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow
red under fluorescent light to allow detection under a microscope.
Before launching Manzano Strategies, Montoya served as Chief of Staff of Los Alamos
National Laboratory’s Nuclear Weapons Program. He served as a senior policy advisor
to Senator Jeff Bingaman, responsible for defense, veterans’ affairs, economic
development and other programs. Donisthorpe was Chief of Staff for Representative Joe
Skeen prior to entering private business as a government affairs advisor for New Mexico
Mining Institute of Technology (New Mexico Tech), among other high-technology and
defense-related clients.
“David and Bruce represent two of the best advisors in the country related to our work with
the government in securing support for programs that will help our veterans and the
military in the field of health care,” said John Cousins, President of Biomoda. “We look
forward to using every bit of their expertise in promoting Biomoda on a national scale.”
Biomoda's. The patented technology, a non-invasive cytology based assay, is designed
for cancer screening of large populations at a reasonable cost. Current diagnostic
methods for lung cancer, including CT scans and X-rays, often detect the disease only at
more advanced stages and are relatively expensive.
Lung cancer claims more lives than any other cancer. The expected 5-year survival rate
for all patients combined in whom lung cancer is diagnosed is 15 percent and by
contrast, the 5-year survival rate for cases detected when the disease is still localized is
50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at
this early stage.
Affairs Efforts
ALBUQUERQUE, N.M., Oct. 25 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin
Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, maker of early lung cancer
detection testing and other cancer diagnostic technology, announced today it hired
Manzano Strategies LLC, a government consulting firm focused on building government
partnerships with companies interested in defense appropriations and development of
advanced technologies.
Manzano Strategies’ (http://www.manzanostrategies.com) partners David Montoya and
Bruce Donisthorpe will spearhead efforts with the New Mexico legislature and federal
government in promoting programs using Biomoda’s early lung cancer detection
technology based on a patented porphyrin application that preferentially binds to
cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow
red under fluorescent light to allow detection under a microscope.
Before launching Manzano Strategies, Montoya served as Chief of Staff of Los Alamos
National Laboratory’s Nuclear Weapons Program. He served as a senior policy advisor
to Senator Jeff Bingaman, responsible for defense, veterans’ affairs, economic
development and other programs. Donisthorpe was Chief of Staff for Representative Joe
Skeen prior to entering private business as a government affairs advisor for New Mexico
Mining Institute of Technology (New Mexico Tech), among other high-technology and
defense-related clients.
“David and Bruce represent two of the best advisors in the country related to our work with
the government in securing support for programs that will help our veterans and the
military in the field of health care,” said John Cousins, President of Biomoda. “We look
forward to using every bit of their expertise in promoting Biomoda on a national scale.”
Biomoda's. The patented technology, a non-invasive cytology based assay, is designed
for cancer screening of large populations at a reasonable cost. Current diagnostic
methods for lung cancer, including CT scans and X-rays, often detect the disease only at
more advanced stages and are relatively expensive.
Lung cancer claims more lives than any other cancer. The expected 5-year survival rate
for all patients combined in whom lung cancer is diagnosed is 15 percent and by
contrast, the 5-year survival rate for cases detected when the disease is still localized is
50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at
this early stage.
 |  |  |
 |
| |
 |
| |
 |
| |
 |